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Abstract 
Purpose: To investigate the toxicological profile of the ethanol extract of Oncoba spinosa (EEOS) after 
acute and sub-chronic administration to rodents. 
Methods: In the acute toxicity study, a single administration of the extract at doses of 2000 and 5000 
mg/kg, respectively, was given to the mice. Mice were observed for general behavioural changes, 
adverse effects and mortality up to 14 days post-treatment. In sub-acute toxicity studies, EEOS was 
given orally to male and female rats at doses of 250 mg/kg, 500 mg/kg and 1000 mg/kg for 28 days. 
Body weight, food intake and water intake were monitored throughout the experimental period; 
hematological parameters, biochemical parameters of the blood and histopathology of various organs 
were also evaluated at the end of the experiment. 
Results: In the acute toxicity study, both the doses used did not cause any mortality or significant 
behavioural changes. Daily oral administration of EEOS for 28 days, in the sub-chronic toxicity study, 
did not show any treatment-related abnormalities with regard to hematological and biochemical 
parameters. There were no significant differences in body weight and organ weight between the control 
and treated groups (p < 0.05). Histological analysis did not show any morphological changes in the 
major vital organs (liver, kidney, stomach, spleen, brain and heart) tested. 
Conclusion: These results demonstrate that the extract may not have any single dose toxicity. The 
LD50 value is greater than 5000 mg/kg. The no-observed adverse effects level (NOAEL) was 
considered to be 1000 mg/kg for male and female rats, respectively. 
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Medicinal plants constitute an important part of 
the health care system for the prevention and 
treatment of various disorders, since the ancient 
civilization. Previous studies have shown that 30 
% of the marketed drugs contain active principles 
that were isolated for the first time from plants 
[1]. Herbal preparations prepared from medicinal 
plants can bring about a solution to certain 
disorders, mostly in developing countries where 
the commercial drugs are expensive and not 
easily available to the poor people [2]. In fact, 
there is lack of evidence on quality, safety and 
efficacy of many herbal preparations. Although 
many herbal preparations are non-toxic, many 
plants currently used for medicines have been 
shown to be highly toxic when given either 
Presanth et al 
Trop J Pharm Res, October 2015; 14(10): 1850  
 
acutely or sub-chronically [3,4]. The increasing 
number of plant based medication users around 
the globe and lack of experimental reports on 
their safety make it basic to direct toxicological 
investigation on natural herbal products [5]. In 
this respect, an earlier study revealed severe 
hepatotoxicity with the utilization of some herbal 
plants [6].   
 
The concern for herbal toxicity has raised anxiety 
among different national and international 
regulatory authorities to figure and execute 
different guidelines for surveying, monitoring and 
preventing toxicity emerging due to herbal 
products. For example, Uppsala Monitoring 
Centre in WHO collates and distributes data with 
respect to unfavourable responses of herbal 
products whereas Organization for Economic 
Cooperation and Development (OECD) sets 
various guidelines and procedures for conducting 
toxicity studies. Many herbal products in the 
market are frequently identified with toxic effects. 
 
Oncoba spinosa, the snuff-box tree, fried egg 
tree or fried-egg flower, is a spiny shrub that 
belongs to family of Flacourtiaceae which has 
about 95 genera and 800-1000 species. The 
leaves are dark, glossy green in colour and 
somewhat leathery and hairless. The fruits are 
grown up to 60 mm in diameter and consists of 
hard shell that becomes dark-reddish brown 
when mature with shiny seeds embedded in a 
dry yellowish pulp [7]. To the best of our 
knowledge, no reports were available on the 
safety profile of this plant despite its traditional 
use in the treatment of diabetes, tumour, 
dysentery and bladder complaints [8].  
 
As a part of safety evaluation, acute and sub 
acute oral dose toxicity studies were carried out 
to investigate the potential toxicity after single 
oral dosing of extract in mice and 28-day 




Collection and identification of plant 
materials 
 
Fresh roots of Oncoba spinosa were collected 
from Tirupathi, Andhrapradesh. The plant was 
identified and authenticated taxonomically by Dr 
K Madhava Chetty of the Department of Botany, 
S.V. University, Tirupathi, AndhraPradesh, India. 
A voucher specimen of the collected sample was 
deposited in the herbarium of the institution for 
future reference. 
 
Preparation of the extract 
 
The roots were shade dried and made into 
coarse powder and extracted with 70 % ethanol 
by cold maceration method for 72 h with 
intermittent shaking. The extract was filtered and 
concentrated at high vacuum and then stored in 




Swiss albino mice (25-30 g) were selected for 
acute toxicity studies and Wistar albino rats of 
both sexes and weighing 130 - 200 g were 
selected for sub-acute toxicity studies. The 
animals had free access to food and water and 
were maintained under standard laboratory 
conditions which included 12-hour light-dark 
cycle and temperature of 28-30 oC.  Animals 
were allowed a one-week acclimatization period 
prior to the study. The experimental protocol was 
approved by the Animal Ethical Committee of the 
Jawaharlal Nehru Technological University, 
Hyderabad, Telangana. 
 
Acute toxicity studies 
 
Acute toxicity studies of ethanolic extract of 
Oncoba spinosa (EEOS) was carried out in 
female mice by using Organisation for Economic 
Co-operation and Development (OECD) 
guideline 425 [9]. Before oral administration of a 
single dose of the test samples, the mice were 
deprived of food for 3 h. Doses of 2000 and 5000 
mg/kg of the test samples were given using oral 
gavage to mice of Group I and Group II 
respectively. All the mice were observed for 
general behavioral changes; symptoms of toxicity 
and mortality after treatment for the first four 
(critical) hours, then over a period of 24 h, 
thereafter daily for 14 days. 
 
Sub-acute toxicity studies 
 
Sub-acute toxicity study (28-day repeated oral 
toxicity study) was carried out according to 
OECD 407 guidelines [10]. Both sexes of rats 
(130-200 g) were divided into four groups with 10 
animals (5 males plus 5 females in each). The 
group I received 1 % carboxylmethylcellulose 
(CMC) vehicle orally at a dose of 10 ml/kg body 
weight and served as a control group whereas 
the rats in groups II, III and IV were treated with 
EEOS at the doses of 250 mg/kg, 500 mg/kg and 
1000 mg/kg body weight continuously up to 28 
days by suspending in 1 % CMC. All the groups 
of rats were observed twice daily for clinical signs 
and the time of onset, duration of these 
symptoms, mortality and morbidity till the 
completion of the experiment. Body weights of 
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the rats in all groups were recorded once before 
the start of dosing, once weekly during the 
treatment period and finally on the day of 
sacrifice. The quantities of food and water intake 
were recorded daily and the data were 
expressed as 7 days cumulative value. At the 
end of the experiment (on 29th day), blood 
samples were collected from the rats after 
overnight fast (but with drinking water allowed) 
by retro-orbital bleeding into heparinized and 
non-heparinized tubes for hematological analysis 
and biochemical analysis, respectively 
 
Hematological parameters  
 
The heparinised blood was used for the analysis 
of hematological parameters such as 
hemoglobin, red blood cell count, white blood cell 
count, platelet count using fully automated 
hematology analyser (PE 6000). 
 
Biochemical parameters  
 
The serum was separated from non-heparinized 
blood and the serum biochemical parameters 
including total cholesterol, creatinine, alanine 
aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase 
(ALP), blood urea nitrogen (BUN), triglycerides, 
total cholesterol, albumin, bilirubin and total 
protein were analysed by using semi-automatic 




After blood collection on day 29, all the animals 
were euthanized for gross pathological 
examinations of all major internal organs. Organs 
such as liver, kidney, stomach, brain, heart and 
spleen were collected from all the animals for 
histopathology. The collected organs were 
weighed and preserved in 10 % neutral buffered 
formalin, trimmed and a 5 μ thickness of tissue 
sections was stained with hematoxylin and eosin 




Results are expressed as mean ± SEM. One way 
ANOVA followed by Dunnett’s test was used for 
data comparison and any p < 0.05 was 




Acute toxicity studies  
 
Oral administration of the EEOS at 2000 mg/kg 
and 5000 mg/kg did not produce any clinical 
signs of toxicity or deaths of the mice. As there 
were no mortality and clinical signs of toxicity in 
both the tested doses, LD50 value of EEOS was 
found to be greater than 5000 mg/kg. 
 
Sub acute toxicity studies 
 
There were no treatment related toxicity signs 
and mortality observed in both sexes of rats 
treated at 250 mg/kg, 500 mg/kg and 1000 mg/kg 
orally during the 4 weeks of treatment. No 
significant differences in body weight were 
observed between the initial and final body 
weight of the rats treated with EEOS and control 
rats (Figure 1). A similar absence of toxic effect 
was observed in the case of food consumption 
(Table 1). There were also no significant 
differences between control and EEOS treated 
groups in organ weight (Table 2). The 
hematological profile of treated and control group 
are summarized in Table 3. All hematological 
parameters such as total red blood cell count, 
total white blood cell count, platelet count, 
hemoglobin, hematocrit and differential leukocyte 
count were within normal range in both control 
and treated groups during the experimental 
period. Sub-acute administration of EEOS did not 
show any significant changes in biochemical 
parameters such as creatinine, urea, 
triglycerides, total cholesterol, total protein, 
albumin, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline 
phosphatase (ALP) and total bilirubin when 
compared to control groups (Table 4). There 
were no statistically significant differences in the 
hematological parameters and biochemical 
parameters measured between control and 
EEOS treated groups. Histopathological 
examinations of the brain, heart, liver, kidney, 
stomach and spleen of the control group mice 
and the mice that received high dose of EEOS 
revealed no abnormalities. The No-Observed 
Adverse Effect level (NOAEL) of the extract was 





Toxicological evaluation has revealed that in both 
acute and sub-acute toxicity test, EEOS did not 
produce any toxic effect in mice. In the acute 
toxicity study, no morbidity or mortality were 
observed in any mice, which survive throughout 
the 14 days of observation.  LD50 value of the 
extract was found to be greater than 5000 mg/kg. 
This finding, therefore, suggests that the extract 
at the limit dose tested is essentially non-toxic 
and safe after oral administration.  
Presanth et al 




Figure 1: Effect of ethanol extract of Oncoba spinosa (EEOS) on body weights in experimental rats in sub-acute 
toxicity study 
 





Sex First week Second week Third week Fourth week 
Control (1% 
CMC) 
Males (n=5) 39.30±1.88 36.55±1.71 42.77±1.87 40.62±1.99 
Females(n=5) 32.50±1.92 37.20±0.98 45.88±1.46 47.51±1.18 
250 mg/kg Males (n=5) 39.07±0.89 36.84±1.18 39.25±1.68 42.04±1.69 
Females(n=5) 38.95±1.50 39.95±1.00 44.94±1.76 47.15±1.12 
500 mg/kg Males (n=5) 35.24±1.40 40.17±2.75 40.22±1.52 42.62±1.60 
Females(n=5) 33.30±1.30 39.08±0.39 42.70±1.47 43.72±1.87 
1000 mg/kg Males (n=5) 37.87±1.47 39.34±1.00 40.20±1.31 45.22±0.47 
Females(n=5) 33.92±0.90 39.92±1.35 43.75±1.32 45.67±1.44 
Values are expressed as mean ± SEM, n = 5 females and 5 males 
 
























Liver 4.28±0.31 4.19±0.26 4.75±0.27 4.68±0.31 4.58±0.37 4.28±0.24 5.07±0.49 3.83±0.25 
Brain 1.45±0.03 1.47±0.05 1.54±0.11 1.65±0.06 1.51±0.09 1.59±0.11 1.72±0.06 1.40±0.07 
Spleen 0.47±0.05 0.45±0.02 0.49±0.05 0.47±0.01 0.46±0.04 0.42±0.04 0.42±0.04 0.41±0.02 
Kidney 1.01±0.06 1.05±0.07 1.01±0.05 1.07±0.04 1.19±0.09 1.08±0.06 1.07±0.07 1.02±0.03 
Heart 0.71±0.03 0.69±0.02 0.61±0.02 0.65±0.01 0.68±0.02 0.70±0.02 0.67±0.05 0.71±0.04 
Stomach 2.57±0.18 2.69±0.17 3.22±0.09 3.25±0.14 2.87±0.21 3.11±0.15 2.80±0.18 3.10±0.17 
Values are expressed as mean±SEM, n=5 females and 5 males 
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Sex Treatment group 
Control 250 mg/kg 500 mg/kg 1000 mg/kg 
Hemoglobin (g/dl) Males (n=5) 13.32±0.73 14.62±0.34 14.36±0.66 14.58±0.83 
Females(n=5) 14.52±0.71 15.34±0.41 15.74±0.50 16.38±0.40 
RBC count (x106/μl) 
 
Males (n=5) 4.76±0.33 4.96±0.31 4.80±0.43 5.22±0.34 
Females(n=5) 5.46±0.30 6.02±0.24 6.54±0.20 6.40±0.32 
WBC count (x103/μl) Males (n=5) 9.10±0.49 8.52±0.61 8.68±0.37 9.78±0.69 
Females(n=5) 10.58±0.40 10.18±0.50 9.29±0.52 10.72±0.36 
Platelet count 
(x103/μl) 
Males (n=5) 827.51±38.04 866.03±40.54 886.38±33.22 903.89±31.38 
Females(n=5) 845.51±42.00 852.03±39.42 860.38±38.97 874.14±18.75 
Hematocrit (%) Males(n=5) 44.32±1.67 46.46±2.22 45.76±1.25 49.74±1.83 
Females(n=5) 40.46±0.84 41.24±1.99 40.56±0.99 42.14±1.83 
Neutrophils (%) Males (n=5) 48.84±2.43 51.50±2.52 54.74±1.89 53.48±1.80 
Females(n=5) 43.84±1.52 44.80±0.53 46.76±0.80 45.36±1.14 
Lymphocytes (%) Males 34.92±1.41 29.62±1.62 34.70±1.80 33.54±2.33 
Females(n=5) 35.66±1.66 31.04±1.02 31.92±1.43 33.98±2.09 
Eosinophils (%) Males(n=5) 3.26±0.48 3.78±0.47 4.06±0.37 4.00±0.34 
Females(n=5) 3.50±0.31 3.76±0.35 3.70±0.36 4.40±0.37 
Monocytes (%) Males(n=5) 5.66±0.39 5.70±0.57 5.82±0.59 5.24±0.19 
Females(n=5) 4.16±0.26 3.96±0.39 3.74±0.67 4.40±0.27 
Basophils (%) Males(n=5) 0.94±0.19 1.30±0.10 1.0±0.22 1.06±0.24 
Females(n=5) 0.84±0.17 0.96±0.24 0.50±0.27 0.66±0.20 
Values are expressed as mean±SEM, n=5 females + 5 males 
 





Sex Treatment group 
Control 250 mg/kg 500 mg/kg 1000 mg/kg 
Creatinine (mg/dl) Males (n=5) 1.40±0.19 1.14±0.27 1.26±0.19 1.02±0.24 
Females(n=5) 1.14±0.19 1.32±0.29 1.00±0.20 1.24±0.28 
Glucose (mg/dl) Males (n=5) 72.18±3.34 81.80±3.24 75.90±2.44 84.38±5.37 
Females(n=5) 91.40±3.68 89.58±3.27 90.62±2.73 101.98±1.34 
Total protein  
(g/dl) 
Males (n=5) 7.18±0.34 6.68±0.27 6.84±0.31 7.12±0.36 
Females(n=5) 6.50±0.36 6.94±0.35 6.76±0.24 7.24±0.37 
ALP (U/L) Males (n=5) 71.18±5.49 82.02±4.39 78.62±4.62 84.62±6.92 
Females(n=5) 81.10±5.33 87.24±3.65 80.28±4.57 95.84±2.35 
AST (U/L) Males(n=5) 51.44±2.63 55.30±2.97 55.44±1.82 53.76±3.53 
Females(n=5) 48.94±2.99 53.90±3.13 54.02±1.68 49.76±2.72 
ALT (U/L) Males (n=5) 44.88±2.86 49.52±1.39 44.26±2.57 45.78±1.46 
Females(n=5) 40.24±0.60 44.62±1.55 43.94±2.56 46.40±2.34 
BUN  (mg/dl) Males(n=5) 28.86±2.21 35.90±1.88 35.86±2.65 33.98±2.03 
Females(n=5) 27.24±1.96 32.72±1.03 31.80±0.74 31.98±0.62 
Triglycerides 
(mg/dl) 
Males(n=5) 66.18±3.13 55.30±2.13 57.68±4.19 67.50±3.69 
Females(n=5) 65.66±2.23 59.30±3.91 60.08±2.42 68.46±2.07 
Total cholesterol 
(mg/dl) 
Males(n=5) 89.46±6.39 78.04±3.56 101.68±1.05 98.40±2.42 
Females(n=5) 80.54±3.53 80.62±2.78 90.90±2.91 90.76±4.02 
Albumin (g/dl) Males(n=5) 3.92±0.28 4.70±0.25 4.64±0.33 4.70±0.18 
Females(n=5) 4.36±0.38 4.24±0.27 4.42±0.24 4.40±0.22 
T.Bilirubin (mg/dl) Males(n=5) 0.84±0.18 1.20±0.13 0.72±0.24 1.26±0.22 
Females(n=5) 0.66±0.18 0.76±0.17 0.50±0.16 0.78±0.25 
Values are expressed as mean ± SEM, n = 5 females + 5 males 
 
The sub-acute dose was selected based on the 
rats LD50 value which kept rats alive, i.e. 1/5, 
1/10 and 1/20 of LD50 value of 5000 mg/kg. In 
repeated dose 28-day oral toxicity study, there 
were no deaths and treatment-related signs were 
observed in all the groups of animals. 
 
Similarly, no significant differences in food and 
water intake, weight gain, biochemical and 
haematological parameters were observed 
between control and treated groups during this 
period. Histopathological examination of selected 
vital organs (heart, brain, liver, kidney, spleen 
and stomach) from both treated and control 
animals showed normal architecture, suggesting 
no microscopic changes and morphological 
disturbances were caused due to oral 
administration of EEOS at highest dose level. 
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Although acute toxicity helps to determine the 
toxicity nature of substances, it is important to 
assess sub-acute toxicity profile because it helps 
to evaluate the morphological and physiological 
changes in organs. It is important to determine 
the food intake and water consumption during 
the investigation of safety of a product with 
medicinal purpose, as proper intake of 
supplements is important to the physiological 
status of the animal and to the achievement of 
best possible response to the compounds under 
investigation [11,12].  
 
In this study, the food intake and water 
consumption were not affected by the 
administration of extract and it did not promote 
any appetite suppression and had no harmful 
effects. Thus, this indicates there was no 
interruption in the metabolism of carbohydrate, 
protein and fat [13]. After exposure to few 
possible toxic substances, there will be changes 
in body weight gain and internal organ weights 
which would reflect toxicity [14]. The body weight 
changes are markers of adverse effects of drugs 
and chemicals and if the body weight loss 
observed is more than 10 % of initial body 
weight, it will be considered as statistically 
significant [15,16]. Organ weight also is an 
important indicator of physiological and 
pathological status of animals. The relative organ 
weight is fundamental to confirm whether the 
organ weight was exposed to the injury or not. 
The heart, liver, kidney, spleen and lungs are the 
primary organs affected by metabolic reaction 
caused by toxicant [17]. There were no 
significant differences in body weight gain 
between control and treated groups. In the 
present study, organ weights in all the treated 
groups of both sexes were not significantly 
different from those of control groups. Hence it 
can be concluded that EEOS is almost non-toxic.  
 
Hematological parameters are some of the most 
sensitive to evaluate the toxicity of medicines in 
humans and animals, and a blood profile 
normally gives important information on the 
reaction of body to damage or stress [18,19]. 
There were no statistically significant, dose-
dependent adverse effects on any of the 
hematological parameters in both male and 
female rats after 4 weeks of EEOS treatment. In 
addition, there were no significant alterations in 
biochemical parameters in all the groups treated 
with a 4-week repeated dose of EEOS. Elevated 
bilirubin values are an indication of altered liver 
functions and a small elevation is an important 
indicator of liver damage in laboratory animals or 
could be a sign of biliary duct obstruction. Liver is 
the primary site for the synthesis of plasma 
proteins especially albumin and alterations in the 
total plasma proteins may indicate liver 
dysfunction [20].  
 
In this study, daily administration of EEOS for 28 
days did not produce any significant changes in 
total protein and albumin of the treated rats from 
all the doses used compared to the control 
group. AST, ALT and ALP are the important 
serum biomarker enzymes usually measured to 
evaluate any toxic effects of the medicines on 
liver [21]. In the present study, no significant 
differences in the levels of AST, ALT and ALP in 
male and female rats were observed. Creatinine 
and BUN are known to be important markers of 
renal dysfunction [18]. Similarly, no significant 
differences in creatinine and BUN values were 
found in treated rats compared with the control 
group. These results suggest that EEOS does 
not have a toxic effect on the liver and kidneys. 
Histological analysis was done to further confirm 
the alteration in cell structure of the organs. The 
histopathological examination is the golden 
standard for evaluating the treatment related 
pathological changes in tissues and organs [22].   
No abnormal findings were observed on 
histopathological examination of all the organs 
examined.  Since no signs of toxicity were 
observed in all the tested groups with respect to 
hematology, biochemistry, organ weights, body 
weights and histopathological examination, it can 
be concluded that EEOS is non-toxic.  Based on 
the results, the No Observed Adverse Effect 
Level (NOAEL) was found to be greater than 




The ethanol extract of the root of O. spinosa is 
relatively safe, as they did not cause death or 
any abnormal changes in both acute and sub-
chronic toxicity studies. Further studies will be 
required to investigate the potential medical 
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